The only two companies that produce a weakened smallpox vaccine for preventing the disease in the elderly and people with weakened immune systems are competing for a U.S. contract worth $1.9 billion, and are doing battle in court for the contract. Bavarian Nordic, a Swedish biotech, has a lawsuit pending in the U.S. against Acambis, alleging Acambis developed its MVA vaccine with BV's research information and technology, amounting to "misappropriation of trade secrets," and seeks to stop Acambis from exporting its vaccine to the U.S.

Related Summaries